+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Microbiome Therapeutics: Global Markets

  • ID: 5174507
  • Report
  • October 2020
  • Region: Global
  • 167 Pages
  • BCC Research
1 of 5
The Global Market for Microbiome Therapeutics Should Grow from $141.7 Million in 2021 to $1.3 Billion by 2026, at a CAGR of 56.4%

FEATURED COMPANIES

  • 4D Pharma
  • Azitra Inc.
  • Eligo Bioscience SAS
  • Kaleido Biosciences
  • Osel Inc.
  • Seres Therapeutics Inc.
  • MORE

The global market for microbiome therapeutics should grow from $141.7 million in 2021 to $1.3 billion by 2026, at a compound annual growth rate (CAGR) of 56.4% for the period of 2021-2026.

  • GIT diseases market for microbiome therapeutics should grow from $87.9 million in 2021 to $222 million by 2026, at a CAGR of 20.4% for the period of 2021-2026.
  • Infections diseases market for microbiome therapeutics should grow from $53.8 million in 2021 to $191.8 million by 2026, at a CAGR of 28.9% for the period of 2021-2026.

This report provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2025.

The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials).

This study surveys the microbiome therapeutics market by application or disease segments: infectious diseases, metabolic diseases, cancer, gut-brain axis and others. The market is also assessed in the following geographic regions: North America, Europe and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting the growth of this market in the global context.

The report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and their leading pipeline candidates. This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.

Excluded from this report are the markets for prebiotics and probiotics labeled as nutritional or dietary supplements. Prebiotics and probiotics, if included, only pertain to when used in the context of microbiome therapy.

The report includes:

  • 32 data tables and 47 additional tables
  • An in-depth overview of the global microbiome therapeutics market
  • Analyses of the global market trends, with data corresponding to market size for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
  • Latest information on market drivers and opportunities, challenges and restraints, technological developments, and regulatory updates, along with their impact on the stakeholders in this market
  • Evaluation of market potential for microbiome therapeutics market, their market share analysis on the basis of product types, applications, and regions
  • Highlights of this innovation driven microbiome therapeutics market covering current trends, disease areas of application, clinical trials and their stages, and new developments
  • Impact of COVID-19 pandemic on the global economy and delay in the clinical trial activity and financial effects on the overall growth of this market
  • Competitive landscape of this market featuring leading biopharmaceutical companies, their products pipeline and company share analysis
  • Key merger and acquisition deals, collaborations and partnerships, licensing and manufacturing agreements, and other notable investment strategies within this market
  • Patent review and deep-dive of the issued patents on the basis of categories such as type, year, disease type, company, country, and assignee
  • Profile description of the major market participants, including Azitra Inc., Evelo Biosciences, LNC Therapeutics, Second Genome and Vedanta Biosciences Inc.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma
  • Azitra Inc.
  • Eligo Bioscience SAS
  • Kaleido Biosciences
  • Osel Inc.
  • Seres Therapeutics Inc.
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research

Chapter 2 Summary and Highlights

  • Key Highlights

Chapter 3 Market and Technology Background

  • The Human Microbiome
  • The Different Microbiomes in Humans
  • Microbiome and Human Health and Disease
  • Technologies Aiding Microbiome Research
  • Microbiome Research Projects
  • Microbiome Therapeutics
  • Strategies for Development of Microbiome Therapeutics
  • Microbiome Therapeutics Disease Areas
  • Regulatory Landscape for Microbiome Therapeutics

Chapter 4 Market Breakdown by Technology Type

  • Market by Microbiome Strategy Type
  • Market Overview
  • Additive Microbiome Therapeutics
  • Modulatory Microbiome Therapeutics
  • Subtractive Microbiome Therapeutics

Chapter 5 Market Breakdown by Application

  • Market by Disease Type
  • Market Overview
  • Market Revenue
  • Market Shares
  • Infections
  • Gastrointestinal (GIT) Diseases
  • Metabolic Diseases
  • Cancer
  • Gut-Brain Axis Diseases
  • Other Diseases
  • Market by Region
  • Market Shares

Chapter 6 Industry Structure

  • Investment in Microbiome Therapeutics
  • Public Funding Initiatives
  • Private Funding Initiatives
  • Collaborations and Partnerships
  • Licensing and Manufacturing Agreements
  • Mergers and Acquisitions
  • Leading Market Players in Microbiome Therapeutics Market
  • Leading Market Players in Additive Microbiome Therapeutics Market
  • Leading Market Players in Modulatory Microbiome Therapeutics Market
  • Leading Market Players in Subtractive Microbiome Therapeutics Market
  • Select Insights from Industry Leaders

Chapter 7 Patent Analysis

  • Patent Analysis
  • Patents by Year
  • Patents by Type
  • Patents by Disease Type
  • Patents by Company
  • Patents by Country
  • Patents by Assignee

Chapter 8 Clinical Trial Analysis

  • Clinical Trial Analysis by Disease Category
  • Share of Clinical Trials
  • Clinical Trial Analysis by Treatment Strategy
  • Share of Clinical Trials
  • Clinical Trial Analysis by Company
  • Share of Clinical Trials
  • Microbiome Therapeutics in Discovery and Preclinical Development
  • Microbiome Therapeutics Clinical Trials in Phase 3

Chapter 9 Analysis of Market Opportunities

  • SWOT Analysis
  • Strengths of Microbiome Therapeutics Market
  • Challenges for Microbiome Therapeutics Market
  • Opportunities for Microbiome Therapeutics Market
  • Threats to the Microbiome Therapeutics Market

Chapter 10 Company Profiles

  • 4D Pharma
  • AO Biome LLC
  • Armata Pharmaceuticals
  • Assembly Biosciences Inc.
  • Azitra Inc.
  • Biomica
  • Biomx
  • Chain Biotechnology Ltd.
  • Eligo Bioscience SAS
  • Enterome SA
  • Evelo Biosciences
  • Finch Therapeutics Group Inc.
  • Intralytix Inc.
  • Kaleido Biosciences
  • Kintai Therapeutics Inc.
  • LNC Therapeutics Inc.
  • MaaT Pharma
  • Osel Inc.
  • Pylum Bioscienes Inc.
  • Quorum Innovations LLC
  • Rebiotix Inc. (Acquired by Ferring Pharmaceuticals)
  • Second Genome
  • Seres Therapeutics Inc.
  • SFA Therapeutics Inc.
  • Synlogic
  • Synthetic Biologics Inc.
  • Vedanta Biosciences Inc.

Chapter 11 Appendix: Acronyms

List of Tables
Summary Table: Global Market for Microbiome Therapeutics, by Disease Type, Through 2026
Table 1: Technologies for Microbiome Research
Table 2: Dysbiosis in Microbiome
Table 3: Leading Pharmaceuticals in Microbiome Therapeutics Partnerships
Table 4: Global Market for Microbiome Therapeutics, by Strategy Type, Through 2026
Table 5: Global Market Shares of Microbiome Therapeutics, by Strategy Type, 2024
Table 6: LBPs in Microbiome Therapeutics
Table 7: Global Market for Additive Microbiome Therapeutics, by Type, Through 2026
Table 8: Global Market Shares of Additive Microbiome Therapeutics, by Type, 2024
Table 9: Modulatory Microbiome Therapeutics
Table 10: Global Market for Modulatory Microbiome Therapeutics, by Type, Through 2026
Table 11: Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2024
Table 12: Global Market for Subtractive Microbiome Therapeutics, by Type, Through 2026
Table 13: Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2024
Table 14: R&D Expenditures in Microbiome Therapeutics, by Company, 2017-2019
Table 15: Global Market for Microbiome Therapeutics, by Disease Type, Through 2026
Table 16: Global Market Shares of Microbiome Therapeutics, by Disease Type, 2024
Table 17: Microbiome Therapeutics in Infections
Table 18: Global Market for Microbiome Therapeutics for Infections, by Region, Through 2026
Table 19: Microbiome Therapeutics in GIT Diseases
Table 20: Global Market for Microbiome Therapeutics for GIT Diseases, by Region Through 2026
Table 21: Microbiome Therapeutics in Metabolic Diseases
Table 22: Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, Through 2026
Table 23: Microbiome Therapeutics in Cancer
Table 24: Global Market for Microbiome Therapeutics for Cancer, by Region, Through 2026
Table 25: Microbiome Therapeutics in Gut-Brain Axis Diseases
Table 26: Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, Through 2026
Table 27: Microbiome Therapeutics in Other Diseases
Table 28: Global Market for Microbiome Therapeutics for Other Diseases, by Region, Through 2026
Table 29: Global Market for Microbiome Therapeutics, by Region, Through 2026
Table 30: Global Market Shares of Microbiome Therapeutics, by Region, 2024
Table 31: Historical Funding Activity in Microbiome Therapeutics, 2015 and 2016
Table 32: Public Funding in Microbiome Therapeutics, 2018-August 2020
Table 33: Venture Funding in Microbiome Therapeutics, 2017-August 2020
Table 34: Collaborations and Partnerships in the Microbiome Therapeutics Market, 2017-August 2020
Table 35: Licensing and Manufacturing Agreements in the Microbiome Therapeutics Market, 2017-August 2020
Table 36: Leading Developers of Additive Microbiome Therapeutics, 2019
Table 37: Leading Developers of Modulatory Microbiome Therapeutics, 2019
Table 38: Leading Developers of Subtractive Microbiome Therapeutics, 2019
Table 39: Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020
Table 40: Patents Issued for Microbiome Therapeutics, by Type, 2017-August 2020
Table 41: Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020
Table 42: Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020
Table 43: Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020
Table 44: Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020
Table 45: Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
Table 46: Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
Table 47: Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Table 48: Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Table 49: Clinical Trials in Microbiome Therapeutics, by Company
Table 50: Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies
Table 51: Microbiome Therapeutics in Discovery and Preclinical Development
Table 52: Microbiome Therapeutics Clinical Trials in Phase 3
Table 53: 4D Pharma’s Pipeline
Table 54: AO Biome’s Pipeline
Table 55: Assembly Biosciences’ Pipeline
Table 56: Armata Pharmaceuticals’ Pipeline
Table 57: Azitra’s Pipeline
Table 58: Biomica’s Pipeline
Table 59: BiomX’s Pipeline
Table 60: Chain Biotechnology’s Pipeline
Table 61: Enterome’s Pipeline
Table 62: Evelo Biosciences’ Pipeline
Table 63: Finch Therapeutics’ Pipeline
Table 64: Intralytix’s Pipeline
Table 65: Kaleido Biosciences’ Pipeline
Table 66: Kintai Therapeutics’ Pipeline
Table 67: LNC Therapeutics’ Pipeline
Table 68: MaaT Pharma’s Pipeline
Table 69: Osel’s Pipeline
Table 70: Quorum Innovations’ Pipeline
Table 71: Rebiotix’s Pipeline
Table 72: Second Genome’s Pipeline
Table 73: Seres Therapeutics’ Pipeline
Table 74: SFA Therapeutics’ Pipeline
Table 75: Synlogic’s Pipeline
Table 76: Synthetic Biologics’ Pipeline
Table 77: Vedanta Biosciences’ Pipeline
Table 78: Acronyms Used in Microbiome Therapeutics

List of Figures
Summary Figure: Global Market for Microbiome Therapeutics, by Disease Type, 2021-2026
Figure 1: Differences in Human Genome and Microbiome
Figure 2: Bacterial Distribution, by Body Site
Figure 3: Essential Functions of Human Microbiome
Figure 4: Dysbiosis and Human Health
Figure 5: Summary of NIH Funding for Microbiome Research, 2012-2016
Figure 6: Global Market for Microbiome Therapeutics, by Strategy Type, 2021-2026
Figure 7: Global Market Shares of Microbiome Therapeutics, by Strategy Type, 2024
Figure 8: Global Market for Additive Microbiome Therapeutics, by Type, 2021-2026
Figure 9: Global Market Shares of Additive Microbiome Therapeutics, by Type, 2024
Figure 10: Global Market for Modulatory Microbiome Therapeutics, by Type, 2021-2026
Figure 11: Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2024
Figure 12: Global Market for Subtractive Microbiome Therapeutics, by Type, 2021-2026
Figure 13: Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2024
Figure 14: Global Market for Microbiome Therapeutics, by Disease Type, 2021-2026
Figure 15: Global Market Shares of Microbiome Therapeutics, by Disease Type, 2024
Figure 16: Global Market for Microbiome Therapeutics for Infections, by Region, 2021-2026
Figure 17: Global Market for Microbiome Therapeutics for GIT Diseases, by Region, 2021-2026
Figure 18: Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, 2021-2026
Figure 19: Global Market for Microbiome Therapeutics for Cancer, by Region, 2021-2026
Figure 20: Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, 2021-2026
Figure 21: Global Market for Microbiome Therapeutics for Other Diseases, by Region, 2021-2026
Figure 22: Global Market for Microbiome Therapeutics, by Region, 2021-2026
Figure 23: Global Market Shares of Microbiome Therapeutics, by Region, 2024
Figure 24: Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020
Figure 25: Patents Issued for Microbiome Therapeutics, by Type, 2017-August 2020
Figure 26: Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020
Figure 27: Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020
Figure 28: Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020
Figure 29: Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020
Figure 30: Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020
Figure 31: Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Figure 32: Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies
Figure 33: SWOT Analysis of the Microbiome Therapeutics Market

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 4D Pharma
  • Azitra Inc.
  • Eligo Bioscience SAS
  • Kaleido Biosciences
  • Osel Inc.
  • Seres Therapeutics Inc.
  • MORE

The microbiome has become a buzz word and attracted millions of dollars in federal grants, awards and funding from venture capitalists. Technological advances in next-generation sequencing and data analytics clubbed with modern approaches of systems biology and genetic engineering have greatly expanded the knowledge of commensal microbial populations and their interactions with the human hosts.

The Human Microbiome Project (HMP), MetaHIT and other independent efforts fueling the exploration of microbiome and its association with human health have led to a research explosion in this area in the last decade. Myriad of studies abound that show that microbiome has a role in mediating many physiological processes such as metabolism, nutrition and immunity. It has been observed in many clinical studies that alterations in the microbial populations or microbial dysbiosis can lead to diseases. As such, modulations of the microbiome such that its normal condition is restored or pathogenic bacteria is eliminated have become potential strategies to address many unmet medical needs. Diseases that still do not have any definitive cure, or available treatments are either not satisfactory or costprohibitive, are being actively targeted as treatment indications by microbiome therapeutics.

There are many active players in the field of microbiome therapeutics, ranging from discovery and clinical-stage to late-stage companies that are exploiting different approaches to modulate the microbiome. Although fecal microbial transplants (FMTs) have been in practice for some time, the use of live biotherapeutic products (LBPs) in the form of single strains or microbial consortia is becoming a widely popular strategy due to targeted mechanisms and controlled production processes. The development of small molecule drugs (postbiotics) and use of phages are also being actively explored.

Currently, no microbiome therapeutic has been approved in the U.S. or in any other market. There are some candidates in Phase 3 trials, such as Seres Therapeutics SER109 and Rebiotix’s RBX2660 that are being evaluated for the treatment of recurrent Clostridium difficile infection. Despite an expansive patent portfolio and a large number of clinical trials in the field of microbiome therapeutics, the market is facing some challenges. The absence of any regulatory framework has created an uncertain situation for many developers in this novel market. The complexity of the human microbiome and variations among different individuals add to the difficulties in the design of clinical trials. Additionally, hurdles are expected during the scaling-up of processes and proving the functional aspects of these drugs.

For the microbiome therapeutics market to grow, a strong collaborative effort is needed from all stakeholders, including the regulatory agencies. Statistically relevant results and proof-of-concept studies driven by technological advances in biomarkers, functional assays, and computational biology are required that will eventually pave the way for product approvals.

Note: Product cover images may vary from those shown
5 of 5
  • 4D Pharma
  • AO Biome LLC
  • Armata Pharmaceuticals
  • Assembly Biosciences Inc.
  • Azitra Inc.
  • Biomica
  • Biomx
  • Chain Biotechnology Ltd.
  • Eligo Bioscience SAS
  • Enterome SA
  • Evelo Biosciences
  • Finch Therapeutics Group Inc.
  • Intralytix Inc.
  • Kaleido Biosciences
  • Kintai Therapeutics Inc.
  • LNC Therapeutics Inc.
  • Maat Pharma
  • Osel Inc.
  • Pylum Bioscienes Inc.
  • Quorum Innovations LLC
  • Rebiotix Inc. (Acquired by Ferring Pharmaceuticals)
  • Second Genome
  • Seres Therapeutics Inc.
  • SFA Therapeutics Inc.
  • Synlogic
  • Synthetic Biologics Inc.
  • Vedanta Biosciences Inc.
Note: Product cover images may vary from those shown
Adroll
adroll